 |
JOURNAL TOOLS |
| eTOC |
| Per abbonarsi |
| Sottometti un articolo |
| Segnala alla tua biblioteca |
ARTICLE TOOLS |
| Publication history |
| Estratti |
| Permessi |
| Per citare questo articolo |
I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW ACUTE LEUKEMIAS IN 2020: STATE OF THE ART Free
Minerva Medica 2020 October;111(5):395-410
DOI: 10.23736/S0026-4806.20.07019-6
Copyright © 2020 EDIZIONI MINERVA MEDICA
lingua: Inglese
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future
Michele GOTTARDI 1, Alessandra SPEROTTO 2, Andrea GHELLI LUSERNA DI RORÀ 3, Antonella PADELLA 3, Delia CANGINI 4, Maria B. GIANNINI 4, Giorgia SIMONETTI 3 ✉, Giovanni MARTINELLI 5, Claudio CERCHIONE 4
1 IRCCS Istituto Oncologico Veneto (IOV), Padua, Italy; 2 Unit of Hematology and Transplant, Dipartimento di Area Medica (DAME), University Hospital of Udine, Udine, Italy; 3 Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy; 4 Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy; 5 IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy
After being in the therapeutic wilderness for several decades, acute myeloid leukemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on CD33 as a target. On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33+ acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and Drug Administration. In this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.
KEY WORDS: Leukemia, myeloid, acute; Gemtuzumab; Clinical Trials as topic; Biomarkers